TY - JOUR
T1 - Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer
AU - Shibata, Tomohiro
AU - Tokunaga, Eriko
AU - Hattori, Satoshi
AU - Watari, Kosuke
AU - Murakami, Yuichi
AU - Yamashita, Nami
AU - Oki, Eiji
AU - Itou, Junji
AU - Toi, Masakazu
AU - Maehara, Yoshihiko
AU - Kuwano, Michihiko
AU - Ono, Mayumi
N1 - Funding Information:
This work is supported by JSPS KAKENHI grants number 17K15508 (T.S.), the Fukuoka Foundation for Sound Health Cancer Research Fund (T.S.), the Life Science Foundation of Japan (M.O.), and St. Mary’s Institute of Health Sciences (K.W., M.K., M.O).
Publisher Copyright:
© Shibata et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - The enhanced expression of the Y-box binding protein YBX1 is consistently correlated with poor outcomes or reduced survival of breast cancer patients. However, the mechanism underlying the association between increased YBX1 expression and poor outcomes has yet to be revealed. We searched a database for the top 500 genes that are positively or negatively correlated with YBX1 and with ESR1 in breast cancer patients. We further examined the association between YBX1-correlated genes and breast cancer outcomes in patients at Kyushu University Hospital. More than 60% of genes that are positively correlated with YBX1 are also negatively correlated with ESR1. The enhanced expression levels of the top 20 positively correlated genes mostly predict negative outcomes, while the enhanced expression levels of the top 20 negatively correlated genes mostly predict positive outcomes. Furthermore, in breast cancer patients at Kyushu University Hospital, the expression levels of YBX1 and YBX1-positively correlated genes were significantly higher and the expression levels of genes negatively correlated with YBX1 were significantly lower in patients who relapsed after their primary surgery than in those who did not relapse. The expression of YBX1 together with the expression of its positively or negatively correlated genes may help to predict outcomes as well as resistance to endocrine therapies in breast cancer patients. Determining the expression of YBX1 and its closely correlated genes will contribute to the development of precision therapeutics for breast cancer.
AB - The enhanced expression of the Y-box binding protein YBX1 is consistently correlated with poor outcomes or reduced survival of breast cancer patients. However, the mechanism underlying the association between increased YBX1 expression and poor outcomes has yet to be revealed. We searched a database for the top 500 genes that are positively or negatively correlated with YBX1 and with ESR1 in breast cancer patients. We further examined the association between YBX1-correlated genes and breast cancer outcomes in patients at Kyushu University Hospital. More than 60% of genes that are positively correlated with YBX1 are also negatively correlated with ESR1. The enhanced expression levels of the top 20 positively correlated genes mostly predict negative outcomes, while the enhanced expression levels of the top 20 negatively correlated genes mostly predict positive outcomes. Furthermore, in breast cancer patients at Kyushu University Hospital, the expression levels of YBX1 and YBX1-positively correlated genes were significantly higher and the expression levels of genes negatively correlated with YBX1 were significantly lower in patients who relapsed after their primary surgery than in those who did not relapse. The expression of YBX1 together with the expression of its positively or negatively correlated genes may help to predict outcomes as well as resistance to endocrine therapies in breast cancer patients. Determining the expression of YBX1 and its closely correlated genes will contribute to the development of precision therapeutics for breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85058496526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058496526&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.26469
DO - 10.18632/oncotarget.26469
M3 - Article
C2 - 30647855
AN - SCOPUS:85058496526
SN - 1949-2553
VL - 9
SP - 37216
EP - 37228
JO - Oncotarget
JF - Oncotarget
IS - 98
ER -
